The efficacy of amantadine hydrochloride in the treatment of COVID-19 - a single-center observation study
© 2021 MEDPRESS..
Coronavirus disease 19 (COVID-19) rapidly spread worldwide. The search for effective measures to counter the development and effects of the pandemic includes: identifying the disease pathogen, introducing methods of reducing its transmission, building the population immunity, and the search for a cure, both among the new and already-known substances with potential antivirus activity such as amantadine hydrochloride.
AIM: The aim of the study was an observational single-center analysis of confirmed COVID-19 cases treated with amantadine in ambulatory settings.
MATERIALS AND METHODS: The 55 patients with confirmed COVID-19 diagnosis were treated in ambulatory settings by amantadine with a treatment schema varied from 200 mg to 500 mg per day. A retrospective analysis was based on symptoms, hospitalization, and number of deaths.
RESULTS: The mean age of the patients was 55.9 years (SD=15), and most patients were male (60%). Despite the majority of patients 64% (n=35) suffering from comorbidities and 53% (n=29) of patients having been diagnosed with pneumonia, none of them died, and only four had required hospitalization in the course of COVID-19. Clinical stabilization was achieved in 91% (n=50) of patients within 48 hours after the first dose of amantadine with further improvement; additionally, all patients experienced remission of COVID-19. In total, 93% (n=51) of patients did not require hospitalization during the treatment.
CONCLUSIONS: The data may suggest that amantadine hydrochloride shows efficacy in preventing hospitalization and deaths in patients with COVID-19. At the same time, it emphasizes that daily monitoring of the patient and regular examination are important in the case of SARS-CoV-2 infection dynamics. It may be justified to carry out a prospective, randomized, and double-blinded clinical study with the postulated amantadine scheme.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego - 49(2021), 294 vom: 16. Dez., Seite 389-393 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bodnar, Włodzimierz [VerfasserIn] |
|---|
| Themen: |
Amantadine |
|---|
| Anmerkungen: |
Date Completed 21.12.2021 Date Revised 03.04.2022 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM334552427 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334552427 | ||
| 003 | DE-627 | ||
| 005 | 20231225223939.0 | ||
| 007 | tu | ||
| 008 | 231225s2021 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1115.xml |
| 035 | |a (DE-627)NLM334552427 | ||
| 035 | |a (NLM)34919079 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bodnar, Włodzimierz |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The efficacy of amantadine hydrochloride in the treatment of COVID-19 - a single-center observation study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 21.12.2021 | ||
| 500 | |a Date Revised 03.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 MEDPRESS. | ||
| 520 | |a Coronavirus disease 19 (COVID-19) rapidly spread worldwide. The search for effective measures to counter the development and effects of the pandemic includes: identifying the disease pathogen, introducing methods of reducing its transmission, building the population immunity, and the search for a cure, both among the new and already-known substances with potential antivirus activity such as amantadine hydrochloride | ||
| 520 | |a AIM: The aim of the study was an observational single-center analysis of confirmed COVID-19 cases treated with amantadine in ambulatory settings | ||
| 520 | |a MATERIALS AND METHODS: The 55 patients with confirmed COVID-19 diagnosis were treated in ambulatory settings by amantadine with a treatment schema varied from 200 mg to 500 mg per day. A retrospective analysis was based on symptoms, hospitalization, and number of deaths | ||
| 520 | |a RESULTS: The mean age of the patients was 55.9 years (SD=15), and most patients were male (60%). Despite the majority of patients 64% (n=35) suffering from comorbidities and 53% (n=29) of patients having been diagnosed with pneumonia, none of them died, and only four had required hospitalization in the course of COVID-19. Clinical stabilization was achieved in 91% (n=50) of patients within 48 hours after the first dose of amantadine with further improvement; additionally, all patients experienced remission of COVID-19. In total, 93% (n=51) of patients did not require hospitalization during the treatment | ||
| 520 | |a CONCLUSIONS: The data may suggest that amantadine hydrochloride shows efficacy in preventing hospitalization and deaths in patients with COVID-19. At the same time, it emphasizes that daily monitoring of the patient and regular examination are important in the case of SARS-CoV-2 infection dynamics. It may be justified to carry out a prospective, randomized, and double-blinded clinical study with the postulated amantadine scheme | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Amantadine hydrochloride | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a Amantadine |2 NLM | |
| 650 | 7 | |a BF4C9Z1J53 |2 NLM | |
| 700 | 1 | |a Aranda-Abreu, Gonzalo |e verfasserin |4 aut | |
| 700 | 1 | |a Słaboń-Willand, Monika |e verfasserin |4 aut | |
| 700 | 1 | |a Kotecka, Sylwia |e verfasserin |4 aut | |
| 700 | 1 | |a Farnik, Małgorzata |e verfasserin |4 aut | |
| 700 | 1 | |a Bodnar, Jarosław |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego |d 1997 |g 49(2021), 294 vom: 16. Dez., Seite 389-393 |w (DE-627)NLM090955315 |x 1426-9686 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2021 |g number:294 |g day:16 |g month:12 |g pages:389-393 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2021 |e 294 |b 16 |c 12 |h 389-393 | ||